Drug · CHEMBL178
DAUNORUBICIN
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. DAUNORUBICIN. Drugs and targets, record CHEMBL178. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL178
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- Daunomycin, Daunorubicina, Daunorubicine, Epirubicin hydrochloride impurity, daunorubicin-, FI 6339, FI-6339, NSC-83142, RP 13057, RP-13057, Valrubicin impurity, daunorubicin
- ChEMBL
- Open Targets' highest stage
- Approval, for 4 of its 39 diseases, from ATC, ClinicalTrials.gov, EMA Human Drugs, FDA and TTD
- Open Targets
Targets1
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| TOP2A | DNA topoisomerase 2-alpha | DNA topoisomerase II alpha inhibitor | INHIBITOR | https://conductscience.org/library/genes/7153 |
Source ChEMBL
Diseases39
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| acute myeloid leukemia | Approval | ClinicalTrials.gov, EMA Human Drugs and FDA | 172 | 170 | https://conductscience.org/library/drugs?q=MONDO_0018874 |
| acute lymphoblastic leukemia | Phase 3 | ClinicalTrials.gov | 52 | 52 | https://conductscience.org/library/drugs?q=MONDO_0004967 |
| myelodysplastic syndrome | Phase 3 | ClinicalTrials.gov | 31 | 30 | https://conductscience.org/library/drugs?q=MONDO_0018881 |
| lymphoblastic lymphoma | Phase 3 | ClinicalTrials.gov | 11 | 11 | https://conductscience.org/library/drugs?q=MONDO_0000873 |
| leukemia | Phase 2 | ClinicalTrials.gov | 6 | 6 | https://conductscience.org/library/drugs?q=MONDO_0005059 |
| non-Hodgkin lymphoma | Phase 3 | ClinicalTrials.gov | 5 | 5 | https://conductscience.org/library/drugs?q=MONDO_0018908 |
| T-cell acute lymphoblastic leukemia | Phase 3 | ClinicalTrials.gov | 4 | 4 | https://conductscience.org/library/drugs?q=MONDO_0004963 |
| myeloid leukemia | Phase 2 | ClinicalTrials.gov | 4 | 4 | https://conductscience.org/library/drugs?q=MONDO_0004643 |
| acute leukemia | Phase 2 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0010643 |
| chronic myeloid leukemia | Phase 3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0011996 |
1 to 10 of 39Source Open Targets
See all 39 diseasesTrials240
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 10 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 26 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT03416179 | A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia | Phase 3 | 730 | 2021-06-25 | daunorubicin | Its name | ClinicalTrials.gov |
| NCT02085408 | Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | Phase 3 | 727 | 2023-03-09 | daunorubicin | Its name | ClinicalTrials.gov |
| NCT00049517 | Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia | Phase 3 | 657 | 2013-02-12 | daunorubicin | Its name | ClinicalTrials.gov |
| NCT00085709 | S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML | Phase 3 | 637 | 2012-08-27 | daunorubicin | Its name | ClinicalTrials.gov |
| NCT00549848 | Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | Phase 3 | 600 | 2022-02-10 | daunorubicin | Its name | ClinicalTrials.gov |
| NCT03512197 | A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML) | Phase 3 | 511 | 2023-06-18 | daunorubicin | Its name | ClinicalTrials.gov |
| NCT00137111 | Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | Phase 3 | 501 | 2011-04-26 | daunorubicin | Its name | ClinicalTrials.gov |
| NCT00703820 | Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia | Phase 3 | 324 | 2018-04-02 | daunorubicin | Its name | ClinicalTrials.gov |
| NCT01696084 | Phase III Study of CPX-351 Versus 7+3 in Patients 60-75 Years Old With Untreated High Risk (Secondary) Acute Myeloid Leukemia | Phase 3 | 309 | 2017-10-02 | cpx-351, daunorubicin | Its name | ClinicalTrials.gov |
| NCT03701308 | Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy | Phase 2/3 | 267 | 2026-01-21 | daunorubicin | Its name | ClinicalTrials.gov |
1 to 10 of 240
See all 240 trialsComparisons in its trials32
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Standard Daunorubicin (Induction Therapy) vs High Dose Daunorubicin (Induction Therapy): serious adverse events | 328 of 328 | 325 of 325 | 653 | NCT00049517 | Trial comparisons |
| Ara-C+Daunomycin vs Ara-C+Daunomycin+Mylotarg: Complete Remission | 203 of 296 | 207 of 300 | 596 | NCT00085709 | Trial comparisons |
| Arm A (CPX-351) vs Arm B (7+3): Proportion of Subjects With a Response | 57 of 153 | 40 of 156 | 309 | NCT01696084 | Trial comparisons |
| Arm A (CPX-351) vs Arm B (7+3): Proportion of Subjects Receiving a Stem Cell Transplant | 52 of 153 | 39 of 156 | 309 | NCT01696084 | Trial comparisons |
| Arm A (CPX-351) vs Arm B (7+3): deaths from any cause | 1 of 153 | 0 of 151 | 304 | NCT01696084 | Trial comparisons |
| Arm A (CPX-351) vs Arm B (7+3): serious adverse events | 90 of 153 | 65 of 151 | 304 | NCT01696084 | Trial comparisons |
| Arm I (Daunorubicin, Cytarabine) vs Arm II (Uproleselan, Daunorubicin, Cytarabine): deaths from any cause | 47 of 136 | 84 of 131 | 267 | NCT03701308 | Trial comparisons |
| Arm I (Daunorubicin, Cytarabine) vs Arm II (Uproleselan, Daunorubicin, Cytarabine): serious adverse events | 12 of 136 | 12 of 131 | 267 | NCT03701308 | Trial comparisons |
| Arm A (CPX-351) vs Arm B (7+3): Rate of Achieving Morphologic Leukemia-free State | 87 of 126 | 66 of 119 | 245 | NCT01696084 | Trial comparisons |
| Arm 1: (HDAC) vs Arm 2:(LDAC): serious adverse events | 23 of 109 | 19 of 114 | 223 | NCT00136084 | Trial comparisons |
1 to 10 of 32
See all 32 comparisons in its trialsPapers from its trials244
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL178
GET https://conductscience.org/api/drugs/v1/CHEMBL178/diseases?page=2